CYCLOPHOSPHAMIDE,DOXORUBICIN & ETOPOSIDE +DDI & GCSF IN HIV+ NONHODGKINS LYMPHOMA

这项第二阶段的多中心试验有几个主要目标。第一项是评价静脉注射环磷酰胺、阿霉素和依托泊苷(CDE)加地高辛(DDI)治疗HIV相关中、高度非霍奇金淋巴瘤(NHL)患者的完全应答率、无进展生存期和生存期。毒性和无事件生存，如死亡、淋巴瘤进展或艾滋病定义事件，也将进行评估。患者将根据CD4计数和中枢神经系统受累情况进行统计。

This Phase II, multicenter trial has several primary objectives. The first is to evaluate the complete response rate, progression-free survival, and survival of patients with HIV-related intermediate and high-grade Non-Hodgkin's Lymphoma (NHL) treated with infusional cyclophosphamide, doxorubicin, and etopside (CDE) plus didanosine (ddI). Toxicity and event-free survival, such as death, progression of lymphoma, or AIDS-defining event, will also be evaluated. Patients will be statified according to CD4 counts and CNS involvement.